A leading developer of placenta-based cell therapy products October 1, 2014
|
|
- Marjory Rose
- 7 years ago
- Views:
Transcription
1 Pluristem Therapeutics, Inc. Initiating Report A leading developer of placenta-based cell therapy products October 1, 2014 Key data Sector Rating Biotechnology BUY Target Price $21.00 Current Market Price $ Week Low/52 Week High $2.58/$4.63 Nasdaq Composite Index 4,555 3-mth avg. volume (in 000 s) Market Cap (in mn) $198.1 Shares Outstanding (in mn) 69.3 Employees 165 Debt 0 Patents Granted 30 Patents Pending 100 Source: Yahoo Finance as of October 1, 2014 and publicly available company documents Company Description: Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental expanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to local and systemic inflammatory and ischemic diseases. These diseases collectively cost the U.S. healthcare system tens of billions of dollars. PLX cells are grown using the Company's proprietary 3D expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, Companyowned, GMP certified manufacturing and research facilities, strategic relationships with pharmaceutical companies and major research institutions, and a seasoned management team. Investment Summary We initiate coverage of Pluristem Therapeutics, Inc. (NASDAQ: PSTI) with a BUY rating and a $21.00/share fair value estimate, based on our Discounted Cash Flow valuation methodology. Accordingly, PSTI s shares should trade at a 590% premium to its current valuation. Our BUY rating is based on the following: PSTI is currently pursuing the development of its PLX cells for 12 different indications that are in various stages of development, from preclinical to Phase II, throughout the world. The company s proprietary 3-dimensional cell growth methods and manufacturing facility have an estimated $1 billion worth of production capacity per year, setting PSTI apart from the rest of the cell therapy market. United Therapeutics (NASDAQ:UTHR) has licensed the exclusive global rights to PLX cells for the treatment of pulmonary arterial hypertension (PAH) in a deal valued at over $55 million. CHA Bio&Diostech (KOSDAQ: ) has licensed the rights to PLX cells for the treatment of peripheral artery disease (PAD) in South Korea, with deal terms including a 50/50 joint venture, CHA covering all costs of clinical trials and subsequently sharing post-commercialization profits equally with PSTI. The U.S. National Institutes of Health are working with PSTI on a development program for PLX cells in the treatment of acute radiation syndrome (ARS). Major Risks to our valuation include the following: Currently, PSTI does not have marketable products with associated revenues, although it does have two out-licensing deals, one of which has already contributed upfront payments to PSTI. Larger, later stage clinical trials may not produce results that are favorable as the company s pre-clinical and earlier stage trials. Key Financial Data FY12 FY13 FY14 Cash and Equivalents (in 000 s) $,9389 $9,323 $9,407 Short Term Investments (in 000 s) $49,412 $44,890 $28,420 Total Assets (in 000 s) $47,420 $68,316 $74,023 Total Stockholder Equity (in 000 s) $37,742 $57,466 $62,123 Source: Company Reports 1 P a g e
2 Investment Merits PSTI cell therapies address $27.5 billion global market... 3D manufacturing process with $1 billion production capacity... United Therapeutics CEO says PSTI s cell therapy is the most transformative of United Therapeutics products in Phase I trials... One of the largest healthcare companies in South Korea partners with PSTI Indications that collectively address $27.5 billion market: PSTI is currently pursuing the development of its PLX cells for 12 different indications that are in various stages of development, from preclinical to Phase II, throughout the world. Treatments for cardiovascular, hematological, pulmonary, orthopedic, and pregnancy indications are being clinically developed by PSTI and its licensees. In Q the Company reported that its Phase I/II trial for treating muscle injury met all primary safety and efficacy endpoints. PLX-PAD treated patients displayed a 500% improvement over the placebo group in the primary efficacy endpoint. The results provide evidence that PLX cells may be efficacious in the treatment of orthopedic injuries including muscles and tendons. In November 2011 the Company reported that its Phase I/II trial for treating critical limb ischemia (CLI) reduced the risk of amputation by 59% compared to historical data. The results provide evidence that PLX cells may be efficacious in the treatment of peripheral artery disease (PAD). Off-the-shelf cell therapy that is mass produced for specific indications is significant advantage in the market: PSTI s proprietary three dimensional cell growth and production methods set it apart from the rest of the cell therapy market. PSTI s cell manufacturing methods enable controlled production of a large quantity of different cell products for specific indications. High quality, homogeneous, commercial-grade cell batches are produced at a price that yields high gross margins. The company s facility, which recently gained approval from the health authorities of Germany, the U.S., European Union, Australia, Israel, and South Korea, has the capacity to produce PLX cells for the treatment of over 150,000 patients annually, an estimated $1 billion in production value. The Company s point of care thawing device provides uniformity of administration, making PLX cells an off-the-shelf cell therapy. Out-licensing deal with United Therapeutics valued at over $55 million addresses $3.3 billion market: United Therapeutics (NASDAQ:UTHR), a $6.5 billion market cap big pharma company, has licensed the exclusive global rights to PLX cells for the treatment of pulmonary arterial hypertension (PAH). PSTI has received a $7 million upfront payment, has the potential to earn up to $38 million more in milestone payments, and up to $10 million towards establishing a manufacturing plant in the USA, plus royalties on gross profits upon regulatory approval. United Therapeutics is now conducting a Phase I study of PLX cells for the treatment of PAH in Australia. PAH, a cardiovascular disease, is incurable and fatal. It is a huge market size, yet only a handful of drugs have been developed to treat the disease. The global market for PAH therapies was $3.3 billion in 2011 and grew at a CAGR of 40% from This means if PSTI captured even 1% of the PAH market upon approval, this one indication alone would contribute $30 million in annual revenues. Licensing & JV Agreement with CHA Bio&Diostech of South Korea: CHA Bio&Diostech (KOSDAQ: ) has licensed the rights to PLX cells for the treatment of peripheral artery disease (PAD) in South Korea. Per the terms of the agreement, a 50/50 joint venture will be established, with CHA covering all costs of clinical trials and subsequently sharing postcommercialization profits equally with PSTI. 2 P a g e
3 U.S. National Institutes of Health assessing PLX-RAD cells for its stockpile of ARS medicine in case of nuclear catastrophe... NIAID is conducting its second study of PLX-RAD cells in the treatment of ARS: The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), is conducting a mechanism-of-action study of PSTI s PLX-RAD cells for the treatment of acute radiation syndrome (ARS). The study aims to investigate the effect of PLX-RAD cells on animals receiving total body irradiation. ARS represents a constellation of signs and symptoms that occur between several minutes and several weeks after exposure to high doses of ionizing radiation. ARS involves multiple organs, including hematological and gastrointestinal systems. The hematological syndrome follows damage to the bone marrow and is characterized by severe decreases in red and white blood cell and platelet counts, which can lead to infection, bleeding and death. The NIAID studies would provide important data to the U.S. government for its Project BioShield and its purchase of national stockpiles of medical countermeasures to nuclear threats. Investment Risks No revenues from approved products... No cell therapies sourced from placental tissues have yet to be approved by the FDA Several companies now have cell therapies in clinical trials.. No products have been approved for sale: Although PSTI is developing therapies for 12 different indications, none has been approved for marketing yet. The high cost of clinical trials and the time required to meet regulatory approval could take years. The company may need to raise additional capital to fund these trials. To date, some of PSTI s studies have been paid for by its big pharma partners. If PSTI s cell therapies do not generate favourable clinical results, the company s partners may look to either stop funding trials or terminate their licensing agreements. Regulatory risk: PSTI s cell therapies are derived from the placenta. To date, the FDA has not any approved cell transplants using manipulated cells derived from placental tissue for any indication. Competitive risk: Several companies are developing cell therapies that are in various stages of clinical development. Some of these companies are comparable in size to PSTI and others are much larger, better funded pharma companies. One or more of these companies may come to market with a cell therapy to treat one or more of the indications for which PSTI currently has therapies in development. 3 P a g e
4 Active Clinical Programs 4 clinical programs targeting $27.5 billion market Near Term Catalysts Several investment triggers upcoming for the balance of 2014 and first half of Outlook...so, our verdict is a BUY on this one With several clinical programs in place, we expect PSTI may achieve clinical results that would trigger additional milestone payments to the company from its big pharma partners. We projected an income statement based on PSTI s clinical programs assuming each product would capture up to 1% market share for each respective indicaiton. The resulting estimated EPS was subjected to standard corporate tax rates. Accordingly, we estimate EPS of $0.40 in 2017 and EPS of $1.25 in We used a discount rate of 15% and a P/E multiple of 25. Valuation Our valuation methodology yields a fair value of $21/share, implying a 590% premium to the current market price. Accordingly, we initiate coverage of PSTI with a BUY rating. 4 P a g e
5 Disclosures: The analysts contributing to this report do not hold any shares of PSTI. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. AcceleronEquity.net certifies that no part of any analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of AcceleronEquity.net. AcceleronEquity.net or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. AcceleronEquity.net uses the following rating system for the securities it covers: Buy: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return of at least 10% over the next 12 months. Neutral: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return between negative 10% and 10% over the next 12 months. Sell: A rating, which at the time it is instituted and or reiterated, that indicates an expectation that the price will depreciate by more than 10% over the next 12 months. Under Review [UR]: A rating, which at the time it is instituted and or reiterated, indicates the temporary removal of the prior rating, price target and estimates for the security. Prior rating, price target and estimates should no longer be relied upon for UR-rated securities. Not Covered [NC]: AcceleronEquity.net does not publish research or have an opinion about this security. 5 P a g e
Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationPLURISTEM THERAPEUTICS (NASDAQCM:PSTI)
UPDATE REPORT Biotechnology Industry November 18, 2009 PLURISTEM THERAPEUTICS (NASDAQCM:PSTI) Early Phase I data encouraging; treatment of first patient cohorts in Germany and the United States commence
More informationFY1Q15 Update Long After Birth, Placenta Still Nurtures (Shareholder Value)
Earnings Update Healthcare November 11, 214 Pluristem Therapeutics (PSTI) Rating: Buy Reni Benjamin, Ph.D. 212-356-542 rbenjamin@hcwresearch.com FY1Q15 Update Long After Birth, Placenta Still Nurtures
More informationClick to edit Master title style. Investor Presentation. June 23, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc.
Click to edit Master title style Investor Presentation June 23, 2016 nuvopharmaceuticals.com Nuvo Pharmaceuticals Inc. Click Safe Harbour to edit Master title style Certain information to be discussed
More informationBDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates
8/11/1 8/1/11 8/3/11 8/5/11 8/7/11 8/9/11 8/11/11 8/1/12 8/3/12 8/5/12 8/7/12 8/9/12 MATELAN Research Preview Note Price as of 9/11/12: 8.69 12 November 212 Company / Sector Fair Value Recommendation BDI
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More informationInvestor Presentation NASDAQ:BLFS
Investor Presentation NASDAQ:BLFS Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the company s anticipated business and
More informationCESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS
CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS Company Completes Year of Transformation, Makes Regulatory Advances in Clinical Programs RANCHO CORDOVA September 29, 2014 Cesca Therapeutics
More informationThe therapies are focused in cardiovascular, orthopedics and neurological indications.
1 2 CescaTherapeutics is (to our knowledge) the first company to integrate all of the essential: 1. Cell friendly devices, 2. Proprietary cell formulations, and Strict clinical steps to ensure the autologous
More informationRaising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements
Raising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements November 2015 Presented by: Stephen Thau 2 BIOTECH IPOS ARE HOT! The Biggest Biotech
More informationG5 Entertainment. G5 Entertainment. Quarter Update Q3 15. Amended strategy and boosted profitability
Quarter Update Q3 15 Last updated on the 18/11/2015 Share Price Market Capitalisation Target Price 41.00 SEK 360.8m SEK 49.05 SEK Amended strategy and boosted profitability reported their third quarter
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationOptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures
Nov 14, 2014 Healthcare OptimizeRx Platform Potential Continues to Grow Other OTC OPRX Buy Rating Unchanged Current Price $0.87 Target Price $4.00 Market Capitalization 20.32M Shares Outstanding 23.36M
More informationTop Ten Things to Know About Stem Cell Treatments
Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationMANNKIND CORPORATION (NASDAQGM: MNKD)
UPDATE REPORT Pharmaceutical Industry February 15, 2013 KEITH A. MARKEY, PH.D., M.B.A. 212-514-7914 KMARKEY@GRIFFINSECURITIES.COM MANNKIND CORPORATION (NASDAQGM: MNKD) CLINICAL TRIALS ON SCHEDULE & FINANCES
More informationJ.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles
J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationSPHERIX INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSector Analysis February 4, 2016
Sector Analysis Analysis of Orphan Drug Market There is significant interest among drug makers and investors alike to focus on the development of products for orphan indications. The reason is these drugs
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationAdaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
More informationRITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY
1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More information5 November 2014 Pharming Group NV. FIRST BERLIN Equity Research. 9M 2014 Results & US Product Launch
FIRST ERLIN Equity Research Netherlands / iotechnology Primary exchange: Euronext Amsterdam / Secondary exchange: Frankfurt 9M 2014 Results & US Product Launch 5 P ha RATING UY PRICE TARGET 1.50 loomberg:
More informationIMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris
More informationCENTRAL SECURITIES CLEARING SYSTEM PLC. CSCS: from West Africa to the rest of the world. Recommendation: BUY
CENTRAL SECURITIES CLEARING SYSTEM PLC NASD EQUITY NIGERIA FINANCIAL SERVICES CSCS: from West Africa to the rest of the world INVESTMENT HIGHLIGHT HALF YEAR 2015: Growing Revenue and Bottom-Line Amidst
More informationico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars)
Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 Balance Sheet (Unaudited) Assets Note September 30, 2012 December 31, 2011 Current assets Cash and cash equivalents 1,478,167
More informationInvestor Presentation
Investor Presentation Nuvo Research Inc. September 14, 2015 TSX: NRI www.nuvoresearch.com Safe Harbour Certain information to be discussed during this corporate update contains forward-looking statements
More informationCreative financing: Private equity in life sciences
: Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access
More informationThermoGenesis Corp. May 2012
ThermoGenesis Corp. May 2012 Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context
More informationBUY. Target: $0.90. Lifesciences - Biotechnology. Live and Let Dye. Investment highlights
Osprey Medical Inc OSP : ASX BUY Target: $0.90 AUS Update 1 Matthijs Smith +61 3 8688 9107 matthijs.smith@canaccord.com.au COMPANY STATISTICS: Share Price $0.45 Valuation $0.90 12 Month Range $0.31 - $0.69
More informationNURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH
NURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH May 2008 This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or
More informationOneMedForumSF 2012 Conference. January 10th
OneMedForumSF 2012 Conference January 10th Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by
More information15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015.
15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com April 17, 2015 Dear Shareholder, We are experiencing exciting times at HemaCare. Over the course of
More information4Q15 Earnings February 2016
4Q15 Earnings February 2016 Forward-Looking Statements The statements contained in this presentation that refer to plans and expectations for the next quarter, the full year or the future are forward-looking
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationGreat Basin Reports 2015 Second Quarter Results and Business Update
Great Basin Reports 2015 Second Quarter Results and Business Update Company Reports 122 Revenue-Generating Customers, Reaffirms Guidance of 170-180 Customers by Year End SALT LAKE CITY, August 12, 2015
More informationOne of the most important recent developments in cancer treatment has been the ability to harvest stem
BIOTECHNOLOGY A Patient-Friendly Approach to Human Cell Transplantation One of the most important recent developments in cancer treatment has been the ability to harvest stem cells from bone marrow or
More informationSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationMATELAN Research. Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES
MATELAN Research Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES 2/5/12 2/7/12 2/9/12 2/11/12 2/1/13 2/3/13 2/5/13 2/7/13 2/9/13
More informationINTERACTIVE BROKERS GROUP ANNOUNCES 1Q2016 RESULTS
INTERACTIVE BROKERS GROUP ANNOUNCES 1Q2016 RESULTS REPORTS COMPREHENSIVE EARNINGS PER SHARE OF $0.60, INCOME BEFORE TAXES OF $337 MILLION ON $489 MILLION IN NET REVENUES, AND EARNINGS PER SHARE ON NET
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationBDI BioEnergy Internat. 14.5 Buy
20/08/13 20/10/13 20/12/13 20/02/14 20/04/14 20/06/14 20/08/14 20/10/14 20/12/14 20/02/15 20/04/15 20/06/15 MATELAN Research Update Note Price as of 20/08/15: 10.80 21 August 2015 Company / Sector Fair
More informationSmall-Cap Research. CytoSorbents Cp (CTSO- NASDAQ) CTSO: Strong Recovery in Product Sales Following Sales Force Restructuring OUTLOOK SUMMARY DATA
Small-Cap Research January 14, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 111 North Canal Street, Chicago, IL 60606 CytoSorbents Cp (CTSO- NASDAQ) CTSO: Strong Recovery in
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationImmunovaccine Inc. (TSX-V: IMV) July 2011
Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities
More informationINTERIM REPORT, 1 January - 30 June 2003
PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement
More informationFinancial Statement and Cash Flow Analysis
Chapter 2 Financial Statement and Cash Flow Analysis Answers to Concept Review Questions 1. What role do the FASB and SEC play with regard to GAAP? The FASB is a nongovernmental, professional standards
More informationSummary of Business Report for the Fifth Fiscal Year ended December 31, 2012
February 15, 2013 Summary of Business Report for the Fifth Fiscal Year ended December 31, 2012 RaQualia Pharma Inc. (4579, Osaka Stock Exchange, Growth Market) today reported financial results for the
More informationSyncordia Technologies and Healthcare Solutions, Corp. Reports Second Quarter Fiscal 2016 Results
Syncordia Technologies and Healthcare Solutions, Corp. Reports Second Quarter Fiscal 2016 Results - Sequential growth of Revenue and Adjusted EBITDA of 15% and 10%, respectively Toronto, Ontario. November
More informationINTERACTIVE BROKERS GROUP ANNOUNCES 2015 RESULTS
INTERACTIVE BROKERS GROUP ANNOUNCES 2015 RESULTS REPORTS COMPREHENSIVE EARNINGS PER SHARE OF $0.62, INCOME BEFORE TAXES OF $458 MILLION ON $1,189 MILLION IN NET REVENUES, AND EARNINGS PER SHARE ON NET
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationFlamel Technologies Announces Second Quarter Results of Fiscal Year 2015
Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Product revenue guidance for 2015 of $170-$185 million reaffirmed Conference call with management to take place at 10:00 am ET on
More informationTRANSCRIPT OF EARNINGS CONFERENCE CALL MAY 16, 2013 AT 9.00 P.M. ET
TRANSCRIPT OF EARNINGS CONFERENCE CALL MAY 16, 2013 AT 9.00 P.M. ET Present: Mohd Aris Bernawi Chairman and CEO President & Secretary Dave Wong Chief Financial Officer Good evening ladies and gentlemen.
More informationIn line performance. Results update 4Q2015. Banks UAE 28 January 2016 DUBAI ISLAMIC BANK
28 Jan 15 28 Apr 15 28 Jul 15 28 Oct 15 DUBAI ISLAMIC BANK In line performance Results update 4Q2015 Banks UAE 28 January 2016 Dubai Islamic Bank s (DIB) reported net profit of AED865mn, in-line with our
More informationCompany Profile // May 2012
Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for
More informationTD is currently among an exclusive group of 77 stocks awarded our highest average score of 10. SAMPLE. Peers BMO 9 RY 9 BNS 9 CM 8
Updated April 16, 2012 TORONTO-DOMINION BANK (THE) (-T) Banking & Investment Svcs. / Banking Services / Banks Description The Average Score combines the quantitative analysis of five widely-used investment
More informationBiotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG
Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its
More informationCorporate Presentation
NASDAQ: BBSI Corporate Presentation November 2012 Forward-Looking Statements Statements in this presentation about future events or performance, including gross revenues and earnings expectations for the
More informationA: SGEAX C: SGECX I: SGEIX
A: SGEAX C: SGECX I: SGEIX NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE Salient Global Equity Fund The investment objective of the Salient Global Equity Fund (the Fund ) is to seek long term capital
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q /X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2000 Commission
More information(800) 715-9999 EMAIL:
DIRECTOR OF RESEARCH: Thomas Ronk PH (800) 715-9999 EMAIL: tom@buyins.net DATE: 5-13-2010 KEY DATA POINTS INSIDE Daily Short Volume CBAI SHORT SELLERS Naked Short Volume Market Maker Friction RECENT CBAI
More informationCreating the Improved Standard in Healthcare Sterile Reprocessing
Creating the Improved Standard in Healthcare Sterile Reprocessing Corporate Presentation May 2016 Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements in this presentation
More informationMEDTRONIC, INC. WORLD WIDE REVENUE (Unaudited)
WORLD WIDE REVENUE ($ millions) 1 2 3 4 1 2 3 4 FY11 FY11 FY11 FY11 FY11 FY12 FY12 FY12 FY12 FY12 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC RHYTHM DISEASE MANAGEMENT
More informationCanadian Tire: Value Under the Hood
Canadian Tire: Value Under the Hood May 2006 Pershing Square Capital Management, L.P. Disclaimer Pershing Square Capital Management's ("Pershing") analysis and conclusions regarding Canadian Tire Corporation
More informationC O R P O R AT E P R E S E N TAT I O N. NASDAQ: BBSI September 2015
C O R P O R AT E P R E S E N TAT I O N NASDAQ: BBSI September 2015 FORWARD-LOOKING STATEMENTS Statements in this presentation about future events or performance, including expectations for gross revenues
More informationInvestor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015
Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Disclaimer 1. This presentation may contain certain forward-looking
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE For media inquiries, contact: Eric Armstrong, Citrix Systems, Inc. (954) 267-2977 or eric.armstrong@citrix.com For investor inquiries, contact: Eduardo Fleites, Citrix Systems, Inc.
More informationStephen G. Brozak sbrozak@wbbsec.com (908) 518-7610 UPDATING COVERAGE NEOPROBE CORPORATION (NYSE-AMEX: NEOP)
WBB Securities, LLC Stephen G. Brozak sbrozak@wbbsec.com (908) 518-7610 UPDATING COVERAGE NEOPROBE CORPORATION (NYSE-AMEX: NEOP) REITERATING STRONG BUY RATING AND 12-MONTH PRICE TARGET OF $9.00 DECEMBER
More informationPower Matters. Acquisition of PMC. October 19, 2015
Power Matters Acquisition of PMC October 19, 2015 Disclaimer Cautionary Note Concerning Forward-Looking Statements Statements in this presentation regarding Microsemi s offer to acquire PMC-Sierra Inc.
More informationRNL BIO CO., LTD. (KOSPI CODE : 003190) Investor Relations 2007
RNL BIO CO., LTD. (KOSPI CODE : 003190) Investor Relations 2007 Jeong Chan Ra President and CEO Safe Harbor This presentation may contain forward looking statements including projections and business trends.
More information(incorporated in the Cayman Islands with limited liability) (Stock Code: 1128 and Debt Stock Code: 5983) INSIDE INFORMATION
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationGlobal Telecom & Technology Reports Fourth Quarter and Full Year 2010 Results
Global Telecom & Technology Reports Fourth Quarter and Full Year 2010 Results MCLEAN, Va. (BUSINESS WIRE Global Telecom & Technology, Inc. ( GTT, (OTCBB: GTLT, a global telecommunications carrier and leading
More informationIntel Reports Second-Quarter Results
Intel Corporation 2200 Mission College Blvd. Santa Clara, CA 95054-1549 CONTACTS: Mark Henninger Amy Kircos Investor Relations Media Relations 408-653-9944 480-552-8803 mark.h.henninger@intel.com amy.kircos@intel.com
More informationQuality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013
Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or
More informationOppenheimer Holdings Inc. Second Quarter 2012 Earnings and Dividend Announcement
Oppenheimer Holdings Inc. NYSE OPY July 27, 2012 New York, NY Second Quarter 2012 Earnings and Dividend Announcement Expressed in thousands of dollars, except per share amounts (unaudited) Three Months
More informationSUMMARY. Risk Level *
March 09, 2015 AGL Resources Inc. Current Recommendation Prior Recommendation Neutral Date of Last Change 03/09/2015 Current Price (03/06/15) $47.11 Target Price $43.00 UNDERPERFORM SUMMARY (GAS-NYSE)
More informationPrivate drilling fluid technology service leader
21 March 2012 Equity Research Report Company Research Petroleum & Petrochemical Sichuan Renzhi Oilfield Technology Services (002629) Investment value analysis report Private drilling fluid technology service
More informationAvacta Group plc! Innovation for global health! Interim Results! 25th April 2012!
Avacta Group plc Innovation for global health Interim Results 25th April 2012 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company
More informationStaples, Inc. Announces First Quarter 2016 Performance
Media Contact: Mark Cautela 508-253-3832 Investor Contact: Chris Powers/Scott Tilghman 508-253-4632/1487 Staples, Inc. Announces First Quarter 2016 Performance FRAMINGHAM, Mass., May 18, 2016 Staples,
More informationXENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14
XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code
More informationCorporate Overview. April 2014 OTCQB: LCDX
Corporate Overview April 2014 OTCQB: LCDX Company Snapshot biopsy Provides non-invasive, point-of-care cellular imaging technologies VivaScope systems can improve patient outcomes while reducing costs
More informationTHE PROMISE OF STEM CELL RESEARCH
THE PROMISE OF STEM CELL RESEARCH MALIGNANT OSTEOPETROSIS AUTOSOMAL RECESSIVE DENSE SCLEROTIC SKELETON HEMATOLOGIC ABNORMALITIES NEUROLOGIC ABNOMALITIES DEATH IN INFANCY OR EARLY CHILDHOOD SUCCESS RATE
More informationTHERMOGENESIS REPORTS THIRD QUARTER RESULTS; REDUCES NET LOSS BY 60 PERCENT
THERMOGENESIS REPORTS THIRD QUARTER RESULTS; REDUCES NET LOSS BY 60 PERCENT RANCHO CORDOVA, CA, (May 6, 2009) ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services
More informationAksa Enerji Outperform (Maintained)
01.14 03.14 05.14 07.14 09.14 11.14 01.15 03.15 05.15 May 26, 2015 Outperform (Maintained) Turkey - Equity - Company Update On the verge of a new era s commissioning of the Company s first lignite power
More information2010 2011 2012E 2013E 2014E
11 April 2012 Equity Research Report Company Research Construction Engineering Zhejiang Yasha Decoration (002375) Comments on 2011 annual results Rapid growth in results, while profit quality continued
More informationCraig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
More informationTrxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3
Siddharth Rajeev, B.Tech, MBA, CFA Analyst November 5, 2015 Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3 Sector/Industry: E-commerce Market Data (as of November 5, 2015) Current Price $1.15 Fair
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationA Phase 2B company treating Secondary Progressive Multiple Sclerosis. Annual General Meeting - August 2014
A Phase 2B company treating Secondary Progressive Multiple Sclerosis Annual General Meeting - August 2014 Forward Looking Statements This Presentation (and any financial information that may be provided
More informationAisling Capital IV, LP
Venture Capital Fund Commitment Aisling Capital IV, LP August 5, 2015 See Last Page for Disclaimer Luke M. Jacobs, Portfolio Manager, Private Markets Overview Aisling Capital IV, LP Venture Capital Fund
More informationBUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value
UK Daily Letter 1 K3 Business Technology Group KBT : AIM : 144p BUY Target: 215p Bob Liao, CFA 44.20.7050.6654 bliao@canaccordgenuity.com COMPANY STATISTICS: 52-week Range: 0.82-1.50 Avg. Daily Vol. (000s):
More informationDeutsche Wohnen AG.» German Jour Fixe 1-1 Conference Merrill Lynch. London, 27 April 2010
Deutsche Wohnen AG» German Jour Fixe 1-1 Conference Merrill Lynch London, 27 April 2010 1 » Agenda 1. Deutsche Wohnen at a glance 2. Results of the financial year 2009 3. Financial highlights 2009 4. Strategic
More informationDavy Defensive High Yield Fund from New Ireland
Davy Asset Management For Financial Advisors Only Davy Defensive High Yield Fund from New Ireland Davy Asset Management is regulated by the Central Bank of Ireland. Exposure to: equity-market type returns
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationDeutsche Wohnen AG.» Full Year Results 2009. Conference Call, 26 March 2010
Deutsche Wohnen AG» Full Year Results 2009 Conference Call, 26 March 2010 1 » Agenda 1. Results of the financial year 2009 2. Financial highlights 2009 3. Strategic objectives 4. Forecast 2 » 1 Results
More informationPharming Group NV (RUCONEST) Chemicals
Pharming Group NV Interim Report January - September Leiden, The Netherlands, 28 October, Biotech company Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) presents its (unaudited)
More information650-527-5152 650-527-6273 SYMANTEC REPORTS FIRST QUARTER FISCAL YEAR 2016 RESULTS
FOR IMMEDIATE RELEASE MEDIA CONTACT: INVESTOR CONTACT: Kristen Batch Sean Hazlett Symantec Corp. Symantec Corp. 650-527-5152 650-527-6273 kristen_batch@symantec.com sean_hazlett@symantec.com SYMANTEC REPORTS
More information